The neurological biomarkers market is expanding as neurological disorders, including dementia and Parkinson's disease, become more prevalent with an aging global population. Innovations in biomarker discovery, particularly in genomics and imaging, are improving diagnostic precision and supporting personalized treatments. Moreover, increased investments in neuroscience research and collaborations between academia and industry are driving the development of novel biomarkers.
LAS VEGAS , Oct. 30, 2024 /PRNewswire/ -- DelveInsight's Neurological Biomarkers Market Insights report provides the current and forecast market analysis, individual leading neurological biomarkers companies' market shares, challenges, Neurological Biomarkers market drivers, barriers, trends, and key market neurological biomarkers companies in the market. Key Takeaways from the Neurological Biomarkers Market Report As per DelveInsight estimates, North America is anticipated to dominate the global neurological biomarkers market during the forecast period.
In the application segment of the neurological biomarkers treatment market, the Alzheimer's disease category captured a significant revenue share in 2023. Notable neurological biomarkers companies such as Abbott, Merck KGaA, Quanterix, Bio-Rad Laboratories, Inc., Banyan Biomarkers, Inc.
, Quanterix, Thermo Fisher Scientific, Fujirebio, Bio-Techne, ADx NeuroSciences NV, F. Hoffmann-La Roche Ltd., BIOMÉRIEUX, Siemens Healthineers, Quibim, C2N Diagnostics, an.
